Ionis Pharmaceuticals Inc
NASDAQ:IONS

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Watchlist
Price: 34.01 USD 0.21% Market Closed
Market Cap: 5.4B USD
Have any thoughts about
Ionis Pharmaceuticals Inc?
Write Note

Ionis Pharmaceuticals Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ionis Pharmaceuticals Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Total Liabilities
$2.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
18%
Abbvie Inc
NYSE:ABBV
Total Liabilities
$137.4B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$36.1B
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$83.4B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$6.6B
CAGR 3-Years
29%
CAGR 5-Years
24%
CAGR 10-Years
18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
21%
No Stocks Found

Ionis Pharmaceuticals Inc
Glance View

Market Cap
5.4B USD
Industry
Biotechnology

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 660 full-time employees. The firm is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The firm has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.

IONS Intrinsic Value
40.4 USD
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Ionis Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
2.4B USD

Based on the financial report for Sep 30, 2024, Ionis Pharmaceuticals Inc's Total Liabilities amounts to 2.4B USD.

What is Ionis Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
18%

Over the last year, the Total Liabilities growth was -8%. The average annual Total Liabilities growth rates for Ionis Pharmaceuticals Inc have been 9% over the past three years , 9% over the past five years , and 18% over the past ten years .

Back to Top